Bayer Secures FDA Approval for Lung Cancer Drug Hyrnuo
Bayer AG has received approval from the US Food and Drug Administration (FDA) for its new medication, Hyrnuo, targeted at treating a prevalent form of lung cancer. This approval is…
New Radioimmunotherapy Shows Promise Against HER2-Positive Breast Cancer
Research published in the November 2025 issue of the Journal of Nuclear Medicine reveals a promising new radioimmunotherapy approach for treating human epidermal growth factor receptor 2 (HER2)-positive breast cancer.…
Optimizing Treatment Choices for HER2-Mutated Lung Cancer Patients
The landscape of treatment for HER2-mutated non-small cell lung cancer (NSCLC) is evolving rapidly. Recent therapeutic developments, including the swift approval of new therapies, underscore the importance of integrating patient…